Kite Pharma
| Publicly traded company | |
| Traded as | NASDAQ: KITE |
| Industry | Biopharmaceutical |
| Founded | 2009 |
| Founder | Arie Belldegrun |
| Headquarters | Santa Monica, California |
|
Key people
|
Arie Belldegrun (Chairman, President and CEO) Paul Jenkinson (CFO) |
| Products | Cancer immunotherapy |
| Website | www.kitepharma.com |
Kite Pharma is a publicly held, clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products with a primary focus on engineered autologous T cell therapy designed to restore the immune system's ability to recognize and eradicate tumors.
The Santa Monica, California-based company was founded in 2009 by Arie Belldegrun, M.D., FACS, an Israeli-American oncologist, who serves as the company's chairman, president and chief executive officer.
In October, Kite Pharma entered into a Cooperative Research and Development Agreement with the National Cancer Institute (NCI) for the development and commercialization of products for the treatment of multiple cancer indications.
In December, the company announced data in its lead clinical development program with the NCI, demonstrating that Kite’s most advanced immunotherapy product candidate – KTE-C19 CAR – can produce robust and durable tumor shrinkage in patients with an aggressive form of non-Hodgkin’s lymphoma, known as diffuse large B cell lymphoma (DLBCL). The clinical data were presented at the 55th American Society of Hematology Annual Meeting.
In March, the company announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development granted orphan drug designation for the company's proposed therapy for DLBCL.
In June, Kite Pharma entered into an exclusive, worldwide license with the National Institutes of Health (NIH) to certain intellectual property related to TCR-based product candidates that target the NY-ESO-1 antigen for the treatment of cancers expressing NY-ESO-1.
In August, Kite Pharma announced findings from its ongoing clinical trial: 12 of 13 evaluable patients with advanced B-cell malignancies had complete remissions (8 patients) or partial remissions (4 patients) resulting in a 92% objective response rate. The results support Kite Pharma's plan to file an Investigational New Drug (IND) application in the fourth quarter of 2014 to initiate a clinical trial of Kite Pharma's lead CAR-based product candidate, KTE-C19, in patients with DLBCL.
...
Wikipedia